The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogen-activated protein kinase

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 3, 2011, Pages

  Halfmann, Peter ^a   Neumann, Gabriele ^a   Kawaoka, Yoshihiro ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN VP24; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; EBOLA VIRUS; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACTIVATING TRANSCRIPTION FACTOR 4; ANTHRACENES; EBOLAVIRUS; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; IMIDAZOLES; INTERFERON-BETA; JNK MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; SIGNAL TRANSDUCTION; VIRAL PROTEINS;

EID: 80054723843     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir325     Document Type: Article

References (15)

1. Sen G. Viruses and interferons. Annu Rev Microbiol 2001; 55:255-81. (Pubitemid 32978106)
2. Randall R, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008; 89:1-47.
3. Platanias L. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Immunol 2005; 5:375-86.
4. Uddin S, Majchrzak B, Woodson J, et al. Activation of the p38 mitogen-activated protein kinase by type interferon. J Biol Chem 1999; 274:30127-31.
5. Versteeg G, Garcia-Sastre A. Viral tricks to grid-lock the type I interferon system. Curr Opin Microbiol 2010; 13:508-16.
6. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B, et al, eds. Fields virology, 5 ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2007: 1409-48.
7. Basler C, Wang X, Muhlberger E, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 2000; 97:12289-94.
8. Prins K, Cardenas W, Basler C. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol 2009; 83:3069-77.
9. Reid SP, Leung L, Hartman A, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol 2006; 80:5156-67.
10. Reid SP, Valmas C, Martinez O, Sanchez F, Basler C. Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily. J Virol 2007; 81:13469-77.
11. Watanabe S, Watanabe T, Noda T, et al. Production of novel Ebola virus-like particles from cDNAs; an alternative to Ebola virus generation by reverse genetics. J Virol 2004; 78:999-1005. (Pubitemid 38067621)
12. Feng Z, Cerveny M, Yan Z, He B. The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNAdependent protein kinase PKR. J Virol 2007; 81:182-92. (Pubitemid 44975159)
13. Kaletsky R, Francica J, Agrawal-Gamse C, Bates P. Tetherin-mediated restriction of filovirus buding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 2009; 106:2886-91.
14. Ishida H, Ohkawa K, Hosui A, et al. Involvement of p38 signaling pathway in interferon-alpha-mediated anitiviral activity toward hepatitis C virus. Biochem Biophys Res Commun 2004; 321: 722-7. (Pubitemid 39118397)
15. Ebihara H, Takada A, Kobasa D, et al. Molecular determinants of Ebola virus virulence in mice. Plos Pathog 2006; 2:0705-11. (Pubitemid 44147423)